ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.
The company will host a teleconference and live audio webcast at 5:30am PT / 8:30am ET; a replay and corporate presentation will be archived on the investor section of the company website.
Details
News Market Reaction – ALXO
On Feb 19, the day this news came out, ALXO closed 12.07% above the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Earnings date
- February 27, 2026
- Scheduled Q4 and full-year 2025 results release before market open
- Conference time PT
- 5:30am PT
- Start time for earnings teleconference and webcast
- Conference time ET
- 8:30am ET
- Start time for earnings teleconference and webcast
Historical Context
-
Underwritten share and warrant offering raising about $150M gross proceeds.
-
Exploratory Phase 1b/2 data linking CD47 expression to evorpacept response.
-
Corporate presentation and fireside chat at J.P. Morgan Healthcare Conference.
-
Progress in ASPEN-09 breast cancer trial and ALX2004 Phase 1 dose escalation.
-
Investigator-sponsored Phase 2 lymphoma data showing high CR and ORR with evorpacept.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.
Fourth Quarter and Full Year 2025 Results Webcast Information
Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET
Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1753123&tp_key=d6cfaba210
Participant Listening Options by Phone: To access the conference call, please dial 1-877- 407-0755 or +1-201-389-0913 and ask to be joined into the ALX Oncology Fourth Quarter and Full Year 2025 Financial Results Conference Call.
Another option for instant telephone access to the event is to use the Call me™ link below:
https://callme.viavid.com/viavid/?callme=true&passcode=13755276&h=true&info=company&r=true&B=6
A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company's website, www.alxoncology.com. An archived webcast will be available on the Company's website after the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.